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In the case of oncolytic virotherapy, understanding the
mechanisms by which cancer cells develop resistance to
infection and lysis is critical to the development of more
effective viral-based platforms. Here, we identify APOBEC3
as an important factor that restricts the potency of oncolytic
vesicular stomatitis virus (VSV). We show that VSV infec-
tion of B16 murine melanoma cells upregulated APOBEC3
in an IFN-b-dependent manner, which was responsible for
the evolution of virus-resistant cell populations and sug-
gested that APOBEC3 expression promoted the acquisition
of a virus-resistant phenotype. Knockdown of APOBEC3 in
B16 cells diminished their capacity to develop resistance
to VSV infection in vitro and enhanced the therapeutic
effect of VSV in vivo. Similarly, overexpression of human
APOBEC3B promoted the acquisition of resistance to onco-
lytic VSV both in vitro and in vivo. Finally, we demonstrate
that APOBEC3B expression had a direct effect on the ﬁtness
of VSV, an RNA virus that has not previously been identi-
ﬁed as restricted by APOBEC3B. This research identiﬁes
APOBEC3 enzymes as key players to target in order to
improve the efﬁcacy of viral or broader nucleic acid-based
therapeutic platforms.Received 12 June 2018; accepted 23 August 2018;
https://doi.org/10.1016/j.omto.2018.08.003.
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Oncolytic virotherapy has been developed for the treatment of cancer
as it combines tumor-tropic cytotoxicity with a highly inﬂammatory
anti-viral response that can activate cellular anti-tumor responses.
Strategies such as tropism targeting and arming of the virus with im-
mune stimulatory cytokines to promote the recruitment of immune
cells to the tumor have signiﬁcantly improved the inherent anti-can-
cer properties of viral therapy.1,2 U.S. Food and Drug Administration
(FDA) approval of the herpes simplex virus (HSV)-based viral ther-
apy talimogene laherparepvec (Tvec), sold as Imlygic, in 2015 demon-
strates the clinical signiﬁcance of these viral-based platforms.3,4
Despite our ability to enhance viral-mediated tumor cell killing andThis is an open access article under the CC BY-Nimmune activation, clinical responses are observed in only a
subset of patients.5,6 To continue to improve upon these responses,
identifying restriction factors that limit viral infection or replication
and that promote resistance to virus replication and spread will be
critical. To this end, we have identiﬁed a novel mechanism by which
tumor cells develop resistance to oncolytic vesicular stomatitis virus
(VSV).
Tumor cells mutate rapidly, giving them a genetic plasticity that al-
lows them to evolve and survive cytotoxic pressure from aggressive
therapies.7 Oncolytic viral therapy exploits genetic and epigenetic
defects in the type I interferon (IFN) signaling pathway that
frequently occur in tumor cells and render them more susceptible
to viral infection and oncolysis.8 Nonetheless, the heterogeneity of
mutations both between tumor types, and even within a single tu-
mor, results in tumors that are able to respond to type I IFN to
varying degrees.9,10 Although IFN-mediated resistance to immuno-
therapy modalities, including viral therapy, have been described,9–12
the speciﬁc mechanisms by which tumor cells develop innate anti-
viral resistance still need to be identiﬁed. Among the IFN-inducible
anti-viral factors, the APOBEC family of cytosine deaminases has
been shown to be involved in both viral resistance and cancer
progression.13,14
The APOBEC3 family of enzymes catalyzes the deamination of
cytosine to uracil on single-stranded DNA (ssDNA). The result-
ing mutation generates a cytosine-to-thymine (C-to-T) transition
and less frequently a cytosine-to-guanine (C-to-G) transversion.15
APOBEC3-mediated viral restriction has largely been characterized
as a response to retroviral infection, although the APOBEC familyMolecular Therapy: Oncolytics Vol. 11 December 2018 ª 2018 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Generation of VSV-Resistant Tumor Cell Populations
(A) Schematic of the generation of VSV-resistant tumor cell populations. 2  104
B16 cells were infected at an MOI of 0.01 with VSV-GFP. Wells were washed
every 2 days to remove dead cells. 7 days later, surviving cells were visible in the
wells (inset). The scale bar represents 0.25 mm. On day 7, wells were trypsinized
and cells were washed 3 in PBS before being replated and reinfected at an MOI
of 0.01 (VSV-GFP). (B) On day 21 after the first infection, surviving cells (B16-
ESCs) were counted. (C) Flow cytometry of B16-ESCs 21 days following initial
VSV infection (open histogram) and uninfected parental B16 cells (gray histogram)
for GFP expression. Events shown are gated from live cell populations. (D) 2  104
B16 cells or B16-ESCs were mock infected or infected at an MOI of 0.01 with
VSV-GFP. The number of surviving cells was counted 24, 48, 72, and 96 hr after
infection. Means ± SD of triplicate wells are shown. ns, not significant; p > 0.05;
**p % 0.01; ****p % 0.0001.
Molecular Therapy: Oncolyticsof proteins also mutates cellular genomic DNA, viral DNA, and
viral RNA genomes.16,17 In addition to acting as viral restric-
tion factors, overexpression of the APOBEC3 family of proteins oc-
curs in many cancer types, and a strong correlation exists between
APOBEC3 upregulation, genomic mutation burden, therapeutic
resistance, and poor prognosis.18,19 The human genome encodes
seven distinct APOBEC3 proteins, while only one APOBEC3 is
encoded in the murine genome.20,21 Speciﬁcally, upregulation of
human APOBEC3B (hAPOBEC3B), which localizes within the nu-
cleus, has been directly implicated with increased mutational burden
among many human cancers and is associated with chemothera-
peutic resistance.22,23 We were therefore interested in determining
whether both murine APOBEC3 (mAPOBEC3) and hAPOBEC3B2 Molecular Therapy: Oncolytics Vol. 11 December 2018can contribute to the generation of tumor cell populations that
are resistant to oncolytic virotherapy.
We demonstrate here that VSV, a negative-sense RNA virus, medi-
ated the upregulation of APOBEC3 in tumor cells. Elevated
APOBEC3 expression was associated with the development of
virus-resistant tumor cell clones, and knockdown of APOBEC3
signiﬁcantly improved VSV therapy in vivo. Furthermore, we
demonstrate that virus passaged through APOBEC3B-overexpress-
ing cells was signiﬁcantly less ﬁt than parental virus. Altogether, our
data demonstrate that APOBEC3 is a key factor that restricts the
efﬁcacy of oncolytic viral therapy.
RESULTS
Resistant Tumor Cell Populations Emerge after Oncolytic Virus
Treatment
We have observed that intratumoral treatment of mice bearing estab-
lished subcutaneous B16 melanoma tumors with VSV resulted in
initial responsiveness to therapy followed by recurrence of the tumor
after treatment.24 These observations suggest that either a pre-exist-
ing population of virus-resistant tumor cell clones is present within
the tumor or that virus infection/replication drives the evolution of
such populations. To investigate how tumor cells acquire resistance
to viral therapy, murine B16 melanoma cells were infected with repet-
itive cycles of VSV-GFP at a low MOI (0.01) in vitro (Figure 1A).
Seven days after initial infection, surviving cells could be recovered,
often as small, distinct colonies (Figure 1A, inset). After two further
rounds of infection at an MOI of 0.01, viable populations of VSV-
resistant cells were recoverable by day 21 after the ﬁrst infection
(B16- escape [ESC]) (Figure 1B). We found that more than 95% of
the live B16-ESC cells were positive for GFP expression, indicating
that they had been infected by the virus (Figure 1C). Most B16-
ESCs at day 21 were both infected and alive, suggesting that the
ESC population was signiﬁcantly more resistant to VSV-mediated on-
colysis than unselected parental B16 cells. To conﬁrm that these col-
onies contained cells that were genuinely resistant to the oncolytic
VSV, we infected either B16 parental cells or B16-ESCs with VSV-
GFP at an MOI of 0.01 and counted the number of surviving cells af-
ter infection. As expected, B16-ESCs infected with VSV-GFP were
able to resist infection and grew at a rate similar to uninfected controls
(Figure 1D).
Oncolytic VSV Resistance Is Associated with an IFN-Dependent
Upregulation of APOBEC3
The selectivity of oncolytic VSV for tumor cells depends upon their
defective IFN signaling pathways. However, a range of IFN respon-
siveness exists for various tumor types.9,10 Consistent with this,
VSV-GFP infection of B16 cells induced moderate levels of type I
IFN expression 48 hours after infection (Figure 2A). Therefore, we
hypothesized that the acquisition of resistance to VSV oncolysis (Fig-
ure 1) may be associated with the expression of IFN-inducible genes
in infected cells. In this regard, the APOBEC3 family of cytosine de-
aminases is well characterized as IFN-inducible genes that can in-
crease the mutational burden within tumor cells, allowing them to
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Figure 2. VSV Resistance Is Associated with IFN-b-Dependent APOBEC3 Induction
(A) Levels of IFN-b were measured from supernatants of wells in which 105 B16 cells were either mock infected or infected with VSV-GFP at an MOI of 0.01 at 0 (pre-
infection), 48, or 96 hr after treatment. (B) Levels of murine APOBEC3 were measured from lysates of wells in which 105 B16 cells were either mock infected or were
infected with VSV-GFP at an MOI of 0.01 at 0 (pre-infection), 24, 48, 72, or 96 hr after treatment. (C) Expression of murine APOBEC3 was measured by western blot
(upper panel) and qRT-PCR (lower panel) from 105 B16 cells infected with VSV-GFP at an MOI of 0.01 at 24 and 48 hr after infection. Levels were normalized to
uninfected control. (D) Levels of murine APOBEC3 were measured by ELISA (left panel) and western blot (right panel) from 105 B16 cells infected with VSV-GFP at an
MOI of 0.01 at 0 (pre-infection), 48, or 96 hr after treatment with a control IgG, a polyclonal anti-IFN-b antibody, or AEB071 (10 mM). (E) 2  104 B16 cells were infected
at an MOI of 0.01 with VSV-GFP with a control IgG, a polyclonal anti-IFN-b antibody, or AEB071 (10 mM) (triplicate wells per treatment). Wells were washed every
2 days to remove dead cells. On day 7, wells were trypsinized and cells were washed 3 in PBS before being replated and reinfected at an MOI of 0.01 (VSV-GFP).
This was repeated for one more cycle of 7-day infection. On day 21 after the first infection, surviving cells were counted. (F) Expression of APOBEC3 RNA was
measured by qRT-PCR from 105 B16 cells or B16-ESCs. Means ± SD of triplicate wells are shown. ns, not significant; p > 0.05; *p% 0.05; **p% 0.01; ***p% 0.001;
****p % 0.0001.
www.moleculartherapy.orgevolve and evade an applied therapy.14,23 Therefore, we investigated
whether APOBEC3 may play a role in the development of resistance
to oncolytic VSV therapy. APOBEC3 was coordinately expressed
with IFN-b following VSV infection, as shown by ELISA and vali-
dated by western blot and qRT-PCR (Figures 2B and 2C). In addition,
antibody-mediated blockade of IFN-b during VSV infection almost
abolished APOBEC3 induction (Figure 2D), as did the inhibitor of
protein kinase C nuclear factor kB (PKC-NF-kB) signaling
AEB071, previously reported as an inhibitor of APOBEC3 induction
through the PKC pathway.25,26 The emergence of VSV-resistant cell
populations (B16-ESCs) was also signiﬁcantly inhibited by either
antibody blockade of IFN-b or PKC-NF-kB signaling inhibition by
AEB071 (Figure 2E). Levels of mAPOBEC3 began to decline by
96 hours after infection (Figure 2B) and were not signiﬁcantly
different in B16-ESCs compared to B16 parental cells at a basal level
(Figure 2F). These data indicate that VSV induces a transient expres-sion of APOBEC3 similar to that seen with classical IFN-stimulated
gene induction.
Altogether, these data led us to hypothesize that VSV-mediated in-
duction of both type I IFN signaling and APOBEC3 expression is
associated with enhanced tumor cell escape from viral oncolysis.
Increased IFN-b Expression Enhances Tumor Cell Resistance
Consistent with a role for type I IFN-induced genes being a key
component in the de novo generation of oncolysis-resistant tumor
cells, low MOI infection of B16 cells for 7 days with VSV-IFN-b27
generated more VSV-resistant colonies than did infection with
VSV-GFP (Figure 3A). Inhibition of PKC-NF-kB signaling by
AEB071 during VSV-GFP or VSV-IFN-b infection signiﬁcantly
inhibited the outgrowth of resistant colonies (Figure 3A). More-
over, signiﬁcantly more VSV-resistant cells were recovered fromMolecular Therapy: Oncolytics Vol. 11 December 2018 3
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Figure 3. Knockdown of APOBEC3 Reduces the Generation of Virus-Resistant Tumor Cell Populations
(A) 2 104 B16 cells were infected at an MOI of 0.01 with VSV-GFP or VSV-IFN-b in the presence or absence of AEB071 (10 mM). Wells were washed every 2 days to remove
dead cells. 7 days later, surviving cells were visualized by crystal violet staining. (B) 2  104 B16 cells were infected at an MOI of 0.01 with VSV-GFP or VSV-IFN-b in the
presence or absence of AEB071 (10 mM). Wells were washed every 2 days to remove dead cells. On day 7, wells were trypsinized and cells were washed 3 in PBS before
being replated and reinfected at an MOI of 0.01 (VSV-GFP or VSV-IFN-b). This was repeated for one more cycle of 7-day infection. On day 21 after the first infection, surviving
cells were counted. (C) Western blot detection of murine APOBEC3 levels in B16 cells transduced with scrambled shRNA, shAPOBEC3 clone 1, or shAPOBEC3 clone 2 or
left untransduced. (D) qRT-PCR of APOBEC3 transcripts from parental B16 or B16 transduced with scrambled shRNA or shAPOBEC3 RNA. (E) Levels of murine APOBEC3
were measured from 105 B16(shAPOBEC3) or B16(scrambled shRNA) cells infected with VSV-GFP or VSV-IFN-b at an MOI of 0.01 at 48 hr after treatment. (F) 2  104
B16(shAPOBEC3) or B16(scrambled) cells were infected at an MOI of 0.01 with VSV-GFP or VSV-IFN-b. Wells were washed every 2 days to remove dead cells. On day 7,
wells were trypsinized and cells were washed 3 in PBS before being replated and reinfected at an MOI of 0.01 (VSV-GFP or VSV-IFN-b). This was repeated for one more
cycle of 7-day infection. On day 21 after the first infection, surviving cells were counted. Means ± SD of triplicate wells are shown. ns, not significant; p > 0.05; *p% 0.05;
**p% 0.01; ****p% 0.0001.
Molecular Therapy: Oncolyticsrepeated virus infection, as in Figure 1A, if cells were infected with
VSV-IFN-b compared to VSV-GFP (Figure 3B). As seen
previously, inhibition of PKC-NF-kB signaling signiﬁcantly
inhibited escape from VSV-IFN-b and, more effectively, from
VSV-GFP (Figure 3B). These data show that IFN-b enhances the
generation of B16-ESC populations through a signaling pathway
that also induces APOBEC3 expression in infected tumor cells.
To demonstrate that APOBEC3 contributed to the acquisition
of resistance to VSV infection, B16 cells in which expression of
APOBEC3 had been knocked down with short hairpin RNA
(shRNA), as shown by ELISA and validated by western blot and
qRT-PCR (Figures 3C–3E), were infected with VSV-GFP or VSV-
IFN-b. Overexpression of IFN-b from VSV led to increased, although
not signiﬁcant, levels of APOBEC3 (Figure 3E) from those induced by
VSV-GFP. The infection of B16(shAPOBEC3) cells with either VSV-4 Molecular Therapy: Oncolytics Vol. 11 December 2018GFP or VSV-IFN-b virus led to both signiﬁcantly lower levels of
APOBEC3 expression (Figure 3E), as well as signiﬁcantly fewer
VSV-resistant B16-ESC populations (Figure 3F), than did infection
of B16 cells transduced with a scrambled, control shRNA (Figures
3C and 3F). These data indicate that although APOBEC3 is
unlikely to be the only IFN-inducible response factor that contributes
to viral resistance, it signiﬁcantly affects the generation of cells that are
able to evade VSV therapy.
APOBEC3 Inhibition Reduces Escape from VSV Therapy
To investigate whether APOBEC3 played an important role in the
in vivo generation of resistance to viral oncolytic therapy, mice
bearing 3-day established B16 parental, B16 (scrambled RNA), or
B16(shAPOBEC3) tumors were injected with nine doses of VSV-
GFP at the site of tumor cell injection. Over two separate experiments,
fewer than 10% of mice injected with B16(shAPOBEC3) tumors
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Figure 4. Knockdown of APOBEC3 Improves VSV Therapy In Vivo
C57BL/6 mice were injected subcutaneously with 2  105 B16(shAPOBEC3) or B16(scrambled) cells. On days 3, 5, 7, 10, 12, 14, 17, 19, and 21, the site of tumor cell
injection was injected with PBS or VSV-GFP (1  108 PFU). The number of mice with detectable tumors (>0.2 cm diameter) at day 55 is shown. Cumulative results from
two separate experiments; n = 8 mice per group.
www.moleculartherapy.orgescaped VSV therapy to form recurrent tumors (Figure 4). In
contrast, 65% of mice with B16(scrambled) tumors escaped VSV
treatment to form recurrent tumors (Figure 4). All PBS-injected
mice developed tumors and required euthanasia by day 25. These
data support the hypothesis that the expression of APOBEC3 contrib-
utes to the outgrowth of VSV-resistant tumors.
hAPOBEC3B Plays a Role in Resistance to Oncolytic VSV
Therapy
hAPOBEC3B has been reported to be involved in the generation of
acquired chemotherapeutic resistance.23 We were therefore inter-
ested in whether hAPOBEC3B may recapitulate the function of
mAPOBEC3 to drive the development of VSV-resistant populations
in a human Mel888 xenograft tumor model. Thus, VSV vectors
expressing four shRNAs against hAPOBEC3B individually or in
combination (shRNAs 1–4) were generated, and knockdown of
hAPOBEC3B in Mel888 cells infected with each vector was
conﬁrmed by western blot (Figure 5A). VSV expressing shRNAs
1–3, as well as the combination of all 4 shRNAs, dramatically
reduced the expression of hAPOBEC3B. A non-speciﬁc band (**)
was observed in all VSV-infected cells, suggesting cross reactivity
of the antibody against a VSV antigen. This was conﬁrmed by
infection with VSV-GFP, which did not result in a reduction
in hAPOBEC3B expression but did show the non-speciﬁc band
(Figure 5A). Similar to induction of mAPOBEC3 in B16 cells (Fig-
ure 2), VSV-mediated induction of APOBEC3B in Mel888 cells was
conﬁrmed using a shorter exposure than that used in Figure 5A, left
panel, which was overexposed to detect any APOBEC3B pro-
tein expressed after shRNA knockdown (Figure 5A, right panel).
Treatment of mice bearing subcutaneous Mel888 tumors with
nine doses of VSV expressing the combination of shRNAs (VSV-
shAPOBEC3B) signiﬁcantly improved survival compared to treat-
ment with VSV-GFP or PBS (Figure 5B). VSV-shAPOBEC3B-
treated mice had controlled tumor growth out to 50 days in contrast
to VSV-GFP mice, which all succumbed to tumor before day 40
(Figure 5C). These data support a role for hAPOBEC3B in promot-
ing resistance to oncolytic VSV therapy.Tumors Overexpressing hAPOBEC3B Readily Escape VSV
Therapy
To test this hypothesis, a mutated, enzymatically non-functional
(Figure 6A, lower panel), or a fully functional hAPOBEC3B protein
(Figure 6A, upper panel) was overexpressed in tumor cells by trans-
duction with a retroviral vector, and expression was conﬁrmed
by western blot and qRT-PCR (Figures 6B and 6C). Robust
hAPOBEC3B expression was observed 72 hr after transduction and
decreased to a lower, yet still elevated, level compared to parental con-
trols by 2 weeks. This could be due to toxicity associated with overex-
pression of hAPOBEC3B, which may act as a mutagen, selecting for
cells that express a lower level of hAPOBEC3B. B16 cells overexpress-
ing the mutated, non-functional APOBEC3B developed resistance to
VSV following a lowMOI infection with VSV-GFP over 21 days (Fig-
ure 6E) at a rate similar to that of parental B16 cells. The growth rate
of the B16-APOBEC3B cell line was not greater than that of the B16-
APOBEC3B MUT or parental B16 cell lines after 5 repeated passages
for 96 hr (out to day 20), indicating that the increased frequency of
VSV escape in the B16-APOBEC3B cell line was not due to altered
growth rates associated with overexpression of APOBEC3B (Fig-
ure 6D). However, B16 cells overexpressing functional APOBEC3B
were better able to resist VSV infection compared to either wild-
type B16 or B16-APOBEC3B MUT (Figure 6E). These effects were
not speciﬁc to the B16 cell line, because increased resistance to VSV
oncolysis was observed in both the murine glioma GL261 and the
human melanoma Mel888 cell lines, when engineered to overexpress
APOBEC3B, after the 21-day treatment period (Figures 6F and 6G).
Transient overexpression of the APOBEC3B protein, but not the
APOBEC3B MUT protein, was associated with a signiﬁcant decrease
in viability of infected B16 cells (Figure 6H). These data show that
the deaminase-competent APOBEC3B protein exerts signiﬁcant
toxicity—possibly through its geno-toxic, mutator activity—which
is absent from the deaminase-incompetent APOBEC3B MUT pro-
tein. However, despite the toxicity of APOBEC3B expression, its
expression allows for greater levels of cell survival upon VSV infection
(Figures 6E and 6F), suggesting that it allows for selection of a virus-
resistant phenotype.Molecular Therapy: Oncolytics Vol. 11 December 2018 5
A B
VS
V-s
hR
NA
 1
VS
V-s
hR
NA
 2
VS
V-s
hR
NA
 3
VS
V-s
hR
NA
 4
VS
V-s
hR
NA
 1-
4
VS
V-G
FP
Un
inf
ec
ted
hAPOBEC3B
**
β-actin
Un
inf
ec
ted
Short exposure
0 4 0 8 0 1 20
0
5 0
1 00
D ay s
P
er
ce
nt
 s
ur
vi
va
l
PBS
VSV-GFP
VSV-shAPOBEC3B
**
***
*
**
*
VS
V-G
FP
C
0 40 80 120
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Days
Vo
lu
m
e 
(c
m
3 )
PBS
0 40 80 120
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
VSV-GFP
Days
Vo
lu
m
e 
(c
m
3 )
0 40 80 120
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Days
Vo
lu
m
e 
(c
m
3 )
VSV-shAPOBEC3B
Figure 5. Knockdown of Human APOBEC3B Improves VSV Therapy in Human Melanomas
(A) Left panel: western blot of hAPOBEC3B expressed in Mel888 cells infected with VSV encoding shRNAs against hAPOBEC3B at an MOI of 0.01. Right panel: western blot
of hAPOBEC3B expressed in uninfected Mel888 cells or in Mel888 infected with VSV-GFP at an MOI of 0.01 at a shorter exposure than in the left panel. (B and C) Kaplan-
Meier survival (B) and tumor volumes (C) of nude mice that were injected subcutaneously with 106 Mel888 cells. On days 3, 5, 7, 10, 12, 14, 17, 19, and 21, tumors were
injected with PBS, 107 PFU VSV-GFP, or a combined dose of 107 PFU of VSV-shAPOBEC3 (shRNAs 1–4); n = 7 mice per group. **p% 0.01; ***p% 0.001.
Molecular Therapy: OncolyticsConsistent with the in vitro data (Figure 6E), B16 tumors overexpress-
ing hAPOBEC3B treated with nine intratumoral injections of VSV-
GFP escaped VSV therapy signiﬁcantly more quickly than control
tumors expressing the mutated APOBEC3B (Figures 7A and 7B).
B16-APOBEC3B MUT-expressing cells were used as the negative
control in these experiments, because previous data indicated target
cell killing is equivalent between B16 parental and B16-APOBEC3B
MUT cell lines (Figure 6E). In addition, low but detectable levels of
VSV-GFP were recovered from most B16-APOBEC3B MUT tumors
at sacriﬁce (Figure 7C). In contrast, no virus was recovered from B16-
APOBEC3B treated tumors (Figure 7C). These data conﬁrm that
overexpression of APOBEC3B in tumors increased the rate at which
tumors escaped from oncolytic virotherapy and suggested that it may
reduce the ﬁtness of the oncolytic virus.
hAPOBEC3B Overexpression Reduces VSV Fitness
Our data have shown that APOBEC3 contributed to generation of
a virus-resistant phenotype of infected tumor cells (Figure 4). In
addition, given the lack of recoverable virus from APOBEC3B-over-
expressing tumors (Figure 7C), and consistent with its role as a
restriction factor against viral infection, we hypothesized that upregu-
lation or overexpression of APOBEC3 or APOBEC3B, respectively,
may also directly affect VSV ﬁtness. Approximately 10-fold less virus
was recovered after repeated passage through B16-APOBEC3B cells
compared to passage through B16-APOBEC3B MUT cells (Fig-6 Molecular Therapy: Oncolytics Vol. 11 December 2018ure 8A). Moreover, when used to reinfect parental B16 cells at
an MOI of 0.01, VSV recovered from 21-day passage through B16-
APOBEC3B cells was signiﬁcantly less cytolytic than both stock virus
and virus recovered from B16-APOBEC3BMUT cells (Figure 8B). To
further characterize the loss of ﬁtness of the virus recovered from
APOBEC3B-overexpressing cells, the burden of defective interfering
particles (DIPs) in the viral population following multiple passages
through either B16-APOBEC3B MUT or B16-APOBEC3B cells was
quantiﬁed. DIP content in each viral passage was quantiﬁed by
measuring the ability of a viral preparation collected after passage
to interfere with infection with a stock virus.28 After a single passage
through either B16-APOBEC3B or B16-APOBEC3B MUT cell lines,
virus recovered after passage interfered equally with infection of
target cells by the stock virus, indicating similar DIP contents (Fig-
ure 8C). However, following ﬁve in vitro passages, virus recovered
from B16-APOBEC3B cells contained signiﬁcantly more interfering
DIPs than did virus recovered from B16-APOBEC3BMUT cells (Fig-
ure 8C). These data showed that there are more non-functional par-
ticles in the supernatant recovered from APOBEC3B-overexpressing
cells, suggesting that APOBEC3B may directly mutate the virus
genome. We are characterizing the APOBEC3B-induced mutations
within the viral genome that lead to this increased DIP content and
reduced viral ﬁtness. Altogether, these data suggest that APOBEC3B
results in decreased oncolytic activity by both facilitating the emer-
gence of tumor cells resistant to oncolytic virus activity and restricting
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Figure 6. Overexpression of Human APOBEC3B Enhances Tumor Cell Escape In Vitro
(A) Tumor cell lines were engineered to overexpress human APOBEC3B following infection with either pBABE-Hygro APOBEC3B or pBABE-Hygro APOBEC3B MUT.
48 hr after infection, bulk populations of cells were selected in hygromycin for 2 weeks and used for experiments. (B and C) 105 murine B16 or human Mel888 cells were
mock infected (lane 1) or were infected at an MOI of 10 with APOBEC3B MUT-expressing viruses (lane 2) or APOBEC3B-expressing viruses (lane 3). Expression of
hAPOBEC3B was assayed by western blot (B) at 72 hr or 14 days after infection or by qRT-PCR at 72 hr after infection (C). (D) 104 B16 parental, B16 APOBEC3B MUT-
overexpressing, and B16-APOBEC3B-overexpressing cells were plated in triplicate wells per cell line, and growth was measured over 96 hr by counting viable cells. Cells
were also grown for 96 hr and then trypsinized, viable cells were counted, and 104 viable cells were replated and grown for a further 96 hr. This regimen was repeated for
a total of 20 days in culture. The number of viable cells at the end of the 20-day culture was measured as shown. (The 21-day point represents the number of cells of each
line grown in the last 96-hr period from an initial plating of 104 viable cells.) (E) 2  104 B16-APOBEC3B or B16-APOBEC3B MUT cells were infected at an MOI of 0.01
with VSV-GFP (triplicate wells per treatment). Wells were washed every 2 days to remove dead cells. On day 7, wells were trypsinized and cells were washed 3 in PBS
before being replated and reinfected at an MOI of 0.01 (VSV-GFP). This was repeated for one more cycle of 7-day infection. On day 21 after the first infection, surviving
cells were counted. (F and G) 2  104 GL261-APOBEC3B or GL261-APOBEC3B MUT cells (F) or MEL888-APOBEC3B or MEL888-APOBEC3B MUT cells (G) were
infected at an MOI of 0.01 with VSV-GFP (triplicate wells per treatment). Wells were washed every 2 days to remove dead cells. On day 7, wells were trypsinized and cells
were washed 3 in PBS before being replated and reinfected at an MOI of 0.01 (VSV-GFP). This was repeated for one more cycle of 7-day infection. On day 21 after the
first infection, surviving cells were counted. Means ± SD of triplicate wells are shown. ns, not significant; p > 0.05; ***p % 0.001; ****p% 0.0001. (H) Cell survival 120 hr
following infection of 105 B16 parental cells with no virus or with pBABE-Hygro APOBEC3B or pBABE-Hygro APOBEC3B MUT viruses (MOI of 10) in the presence of
polybrene (triplicate wells per infection).
www.moleculartherapy.orgthe ﬁtness of the virus directly by altering the viability of progeny
particles.
DISCUSSION
The tumor tropism of oncolytic viruses is associated with an impaired
innate anti-viral signaling response frequently characterized in malig-
nancies. However, the ability of tumor cells to produce and/orrespond to type I IFN can differ greatly. Such heterogeneity is likely
to be a signiﬁcant factor affecting the variability in responses observed
in clinical trials with oncolytic viral therapies. To understand the
mechanisms underlying escape from oncolytic virus therapy, we stud-
ied tumor cells that became resistant to oncolytic VSV over several
rounds of infection. The development of virus-resistant cells was
associated with the upregulation of the mAPOBEC3 cytosineMolecular Therapy: Oncolytics Vol. 11 December 2018 7
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Figure 7. Overexpression of APOBEC3B Decreases
the Efficacy of VSV Therapy In Vivo
(A and B) C57BL/6 mice were injected subcutaneously
with 2  105 B16-APOBEC3B or B16-APOBEC3B
MUT cells. On days 10, 12, 14, 17, 19, 21, 24, 26,
and 28, the site of tumor cell injection was injected with
PBS or VSV-GFP (1  108 PFU). Tumor growth (A) and
overall survival (B) are shown. The number of mice with
detectable tumors (>0.2 cm diameter) at day 55 is
shown. Cumulative results from two separate experi-
ments; n = 8 mice per group. (C) Tumors were collected
at time of sacrifice, and viral titer was determined by
plaque assay. Means ± SD of triplicate wells are shown.
ns, not significant; p > 0.05; **p % 0.01; ***p % 0.001;
****p % 0.0001.
Molecular Therapy: Oncolyticsdeaminase in an IFN-b-dependent manner. Our results here identify
a role for APOBEC3 as an important factor that restricts the efﬁcacy
of oncolytic virotherapy.
The APOBEC3 family of proteins has been shown to be important
in the restriction of retroviruses, herpesviruses, and hepatitis vi-
ruses.13,19,29,30 One mechanism of APOBEC3-mediated retrovirus
mutagenesis involves the deamination of cytosine to uracil on ssDNA
during the reverse transcription of the viral genome.31 APOBEC3
proteins have also been shown to act on cellular RNA substrates32,33
and were implicated to mediate resistance to cornavirus infection, a
positive-sense RNA virus.34 In addition, APOBEC3 has mutagenic
activity directly on cellular DNA and has been identiﬁed as a key
driver for tumorigenesis and disease progression.14,16,18 The dual
properties of APOBEC3 as both an anti-viral restriction factor and
a cancer mutation driver led us to hypothesize that APOBEC3 may
play a role in restricting oncolytic viral infection and/or replication
in tumor cells (Figure 1).8 Molecular Therapy: Oncolytics Vol. 11 December 2018We observed a signiﬁcant upregulation of
APOBEC3 48–72 hours post-infection coinci-
dent with the upregulation of IFN-b (Figures
2A–2C). Blockade of IFN-b, or PKC signaling
with the small molecule inhibitor AEB071,
blocked APOBEC3 expression following infec-
tion and correspondingly led to a reduction in
the number of surviving virus-resistant cells (Fig-
ures 2D and 2E). Moreover, infection of B16 cells
with VSV expressing murine IFN-b signiﬁcantly
increased the number of treatment-resistant cells
even after a single round of infection (Figure 3A),
an effect that was abrogated by AEB071 (Figures
3A and 3B). Many classical type I IFN-stimulated
genes have been identiﬁed as mediators of resis-
tance to VSV viral therapy, and the use of
broadly acting JAK/STAT inhibitors has been
suggested to counteract these IFN responses to
improve oncolytic therapy.11,35 However, our
data here are the ﬁrst to identify APOBEC3 asa key type I IFN-stimulated gene that contributes to resistance to on-
colytic viral therapy.
Consistent with the role of APOBEC3 activity in mediating the devel-
opment of resistance to VSV oncolysis, fewer VSV-resistant surviving
cells were recovered following in vitro infection with VSV-GFP or
VSV-IFN-b if APOBEC3 expression was inhibited using shRNA (Fig-
ure 3F). In addition, the in vivo efﬁcacy of VSV oncolytic therapy was
signiﬁcantly improved by APOBEC3 knockdown. Less than 10% of
mice implanted with tumors expressing APOBEC3 shRNA developed
tumors after an aggressive treatment of nine doses of intratumoral
VSV-GFP, whereas tumor outgrowth was observed in 100% of mice
implanted with B16 parental cells and 65% of mice implanted with
B16 cells expressing a scrambled shRNA (Figure 4). Furthermore,
speciﬁc targeting of hAPOBEC3B by shRNA expressed from VSV
signiﬁcantly improved the control of tumor growth and survival of
nude mice bearing human Mel888 melanomas (Figure 5B), thereby
implicating the human APOBEC3 family in the acquisition of
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Figure 8. APOBEC3B Directly Affects the Fitness of VSV
(A) 2 104 B16-APOBEC3B or B16-APOBEC3B MUT cells were infected at an MOI of 0.01 with VSV-GFP from a parental stock of titer 5 109 PFU/mL (triplicate wells per
treatment). Wells were washed every 2 days to remove dead cells. On day 7, supernatant was removed, the wells were trypsinized, and cells were washed 3 in PBS before
being replated. These replated cells were then reinfected with the 7-day virus supernatants for a further 7 days. This was repeated for one more cycle of 7-day infection. On
day 21 after the first infection, virus was recovered (VSV-ESC) and titered. (B) Parental stock VSV-GFP or VSV-ESC viruses were used to infect 105 parental B16 cells at an
MOI of 0.01, as determined from the titers in (A). 5 days after infection, surviving cells were counted. (C) 1 106 B16-APOBEC3BMUT or B16-APOBEC3B cells were infected
at an MOI of 0.01 for 24 hr. Virus from the supernatant was collected, and 1 mL of supernatant was used to reinfect a fresh monolayer of 1  106 B16-APOBEC3B MUT or
B16-APOBEC3B cells. Viral supernatants collected from serial passage were diluted from 101–106 and used to infect 2 104 BHK cells. The virus was allowed to adsorb
for 1 hr at 37C and then were washed from the well, followed by infection with VSV-GFP stock virus at an MOI of 20. Supernatant was collected 24 hr after infection
and analyzed by plaque assay to determine the titer of virus produced. Means ± SD of triplicate wells are shown. ns, not significant; p > 0.05; *p% 0.05; ***p % 0.001;
****p% 0.0001.
www.moleculartherapy.orgresistance to oncolytic viral therapy. The human genome encodes six
additional APOBEC3 proteins, with distinct patterns of expression,
subcellular localizations, and biochemical and anti-viral activities.18,36
In particular, human APOBEC3A, APOBEC3F, and APOBEC3G are
also known to be IFN inducible.37,38 Therefore, it will be of great in-
terest to expand the studies described here to investigate the role of
these additional human APOBEC3 enzymes in restricting the efﬁcacy
of VSV or other oncolytic viruses.
Our data indicate that inhibition of APOBEC3 enzymes may be a
viable strategy to improve VSV oncolytic viral therapy in vivo. The
implications for viral restriction by APOBEC3 extend beyond onco-
lytic therapy and include gene therapy protocols using retroviral or
lentiviral vectors whose natural life cycle has been largely associated
with APOBEC3 restriction. Although there are no clinically approvedinhibitors of APOBEC3B enzymes, the use of inhibitors such as
AEB071 may indirectly block APOBEC3 upregulation, and targeted
knockdown of APOBEC3 by shRNA delivered from a viral vector
may be a viable strategy to circumvent APOBEC3-mediated viral
resistance.
When tumor cells overexpressing hAPOBEC3B were treated with
VSV for 21 days in vitro (Figures 6E–6G), we observed a signiﬁcant
increase in the number of virus-resistant, surviving cells compared
to APOBEC3B MUT-overexpressing cells. APOBEC3B-associated
anti-viral resistance did not depend on cell or tumor type, as over-
expression of functional APOBEC3B in murine glioblastoma GL261
and human melanoma MEL888 cells also resulted in increased
numbers of virus-resistant surviving cells after treatment (Figures
6F and 6G). Similarly, VSV treatment was better able to controlMolecular Therapy: Oncolytics Vol. 11 December 2018 9
Molecular Therapy: OncolyticsB16-APOBEC3B MUT tumors compared to B16-APOBEC3B
tumors (Figures 7A and 7B). Virus was not recovered from B16-
APOBEC3B tumors at the time of sacriﬁce, while titers up to 104
plaque-forming units (PFU)/mL were recovered from B16-
APOBEC3B MUT tumors, suggesting that APOBEC3B had a direct
effect on viral replication and persistence in vivo (Figure 7C).
We observed that overexpression of APOBEC3B is toxic in that
elevated levels of APOBEC3B were seen within 72 hr after transfec-
tion or infection and then returned to lower levels within 2 weeks
(Figure 6B). To explain this observation, in which APOBEC3B
expression returns to background levels in the long term, we hy-
pothesize that mutagenesis by APOBEC3B is tolerable up to a
certain threshold within any given cell, over and above which crit-
ical mutations are induced, leading to cell lethality. In those cells in
which overexpression of APOBEC3B does not reach this threshold,
and in which APOBEC3B overexpression is selected against, cell
survival is possible. This is consistent with our observation that
transient overexpression of APOBEC3B, but not APOBEC3B
MUT, was associated with a signiﬁcant decrease in viability
of infected B16 cells (Figure 6H) and that the long-term
growth rate of B16 APOBEC3B cells was lower than that of B16
APOBEC3B MUT or B16 parental cells (Figure 6D). However,
we observed a similar trend in the reduction of APOBEC3B
MUT expression over 14 days (Figure 6B). In this respect, we
cannot exclude that additional deaminase-independent activities
of APOBEC3B may be preserved in the APOBEC3B MUT protein
and that these additional deaminase-independent activities of the
APOBEC3B and APOBEC3B MUT proteins may help to select
only those cells in which expression of the transgene is selectively
downregulated.
To understand whether APOBEC3 had a direct effect on the viral
platform, VSV-GFP was passaged through B16-APOBEC3B MUT
or B16-APOBEC3B cells. Approximately 10-fold less VSV-GFP
was recovered from serial passage through APOBEC3B-overex-
pressing cells compared to virus recovered from APOBEC3B
MUT-overexpressing cells (Figure 8A). In addition, virus recovered
from several passages through APOBEC3B-overexpressing cells was
signiﬁcantly less oncolytic in parental B16 cells than either virus
recovered from APOBEC3B MUT-overexpressing cells or parental
stock virus (Figure 8B). Analysis of the virus generated after a single
passage, although each cell line revealed a similar induction of the
cytopathic effect and no signiﬁcant difference in the content of
DIPs (Figure 8C). However, after ﬁve passages, virus recovered
from B16-APOBEC3B cells contained signiﬁcantly more DIPs, as
measured by its ability to interfere with infection of cells by a stan-
dard stock of virus, hence conﬁrming that hAPOBEC3B activity
directly affected the ﬁtness of the viral progeny generated during
infection (Figure 8C). To our knowledge, this is the ﬁrst report of
APOBEC3-mediated anti-viral resistance to VSV infection. We are
testing two hypotheses to explain these observations. First, direct
mutagenic activity of APOBEC3B on the VSV RNA genome would
generate mutations that decrease the ﬁtness of the viral quasispecies.10 Molecular Therapy: Oncolytics Vol. 11 December 2018Alternatively, APOBEC3B activity on the host cell population may
generate cellular environments in which viral replication is signiﬁ-
cantly inhibited. To distinguish between these two possibilities, we
are sequencing the viruses that emerge from passage through
B16 parental, B16-APOBEC3B MUT, or B16-APOBEC3B cells, as
well as characterizing changes in the anti-viral phenotype of the
APOBEC3B-modiﬁed cells.
Altogether, our data show that oncolytic viral infection with VSV
induces a type I IFN-dependent upregulation of APOBEC3 that
promotes the generation of virus-resistant tumor cell populations
and reduces the oncolytic ﬁtness of the virus. Our results identify
APOBEC3 as a rational target to improve the efﬁcacy of oncolytic
platforms and other viral-based therapies. We are investigating
the particular targets of APOBEC3-mediated mutation that are
responsible for tumor cell escape from VSV oncolysis, as well as
the viral genomic targets that reduce viral ﬁtness. Our preliminary
studies have conﬁrmed that APOBEC3 overexpression generates
signiﬁcant levels of cellular genomic mutations, and we are testing
the hypothesis that at least some of these act to decrease viral repli-
cation. Finally, we are pursuing strategies that target APOBEC3 dur-
ing virus infection to improve the therapeutic outcome of oncolytic
viral therapy.
MATERIALS AND METHODS
Cell Lines
Murine melanoma B16 cells were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS). B16TK cells were derived from
a B16.F1 clone transfected with a plasmid expressing the herpes sim-
plex virus 1 thymidine kinase (HSV-1 TK) gene. Following stable
selection in 1.25 mg/mL puromycin, these cells were shown to be sen-
sitive to ganciclovir (Cymevene) at 5 mg/mL.39–41 B16-APOBEC3B
and B16-APOBEC3B MUT cells were maintained in DMEM supple-
mented with 10% FBS at 37C in 10% CO2 and selected in hygrom-
ycin (200 mg/mL). Baby hamster kidney (BHK) cells were cultures
in DMEM supplemented with 10% FBS. All cell lines weremaintained
at 37C in 10% CO2 and regularly shown to be free of Mycoplasma
infection.
Mice
6- to 8-week-old female C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, Maine).
Viruses
VSV was generated from pXN2 cDNA plasmid using the estab-
lished reverse genetics system in BHK cells.42 All transgenes were
inserted between viral G and L protein using the XhoI and NheI re-
striction sites. Virus titers were determined by plaque assay on
BHK cells.
Generation of Virus-Resistant Cell Lines
B16 cells were infected at an MOI of 0.01 (VSV) for 1 hr, washed with
PBS, and then incubated for 7 days. Dead cells were removed every
2 days by washing with PBS. After 7 days, the cells were collected
www.moleculartherapy.orgby detachment with trypsin and replated. These cells were subjected
to two repeated rounds of infection as previously described. After
21 days, or three total rounds of infection, the remaining virus-
escaped cells were collected. This protocol was performed in the
presence or absence of anti-IFN-b antibody (rabbit polyclonal anti-
mouse IFN beta; PBL InterferonSource, Piscataway, New Jersey),
PKC signaling inhibitor (AEB071, 10 mM; MedChemExpress,
Monmouth Junction, New Jersey), or control immunoglobulin G
(IgG) (Chrome Pure anti-rabbit IgG, catalog no. 011-000-003;
Jackson Laboratory).
Protein Quantification
mAPOBEC3 was measured by western blot using a rabbit mono-
clonal anti-APOBEC3 (184990; Abcam, San Francisco, California);
hAPOBEC3B was measured by western blot using a rabbit poly-
clonal anti-APOBEC3B PA5-11430 (Thermo Fisher Scientiﬁc).
mAPOBEC3 was measured by rabbit monoclonal anti-hAPOBEC3B
ELISA (Abcam, San Francisco, California), which reacts with both
hAPOBEC3B and mAPOBEC3, according to the manufacturer’s in-
structions. Murine IFN-b was measured by direct ELISA (R&D
Systems) according to the manufacturer’s instructions.
qRT-PCR
RNAwas preparedwith the RNeasyMini Kit (QIAGEN,Valencia, Cal-
ifornia). 1mg total RNAwas reverse transcribed in a 20mL volumeusing
oligo-(dT) primers using the First Strand cDNA Synthesis Kit (Roche,
Indianapolis, Indiana). A cDNA equivalent of 1 ng RNA was ampli-
ﬁed by PCR with gene-speciﬁc primers using GAPDH as loading con-
trol (mgapdh sense, 50-TCATGACCACAGTCCATGCC-30; mgapdh
antisense, 50-TCAGCTCTGGGATGACCTTG-30; APOBEC3 sense,
50-ATGGGACCATTCTGTCTGGGA-30; and APOBEC3 antisense,
50-TCAAGACACGGGGGTCCAAG-30). qRT-PCR was carried out
using a LightCycler480 SYBR Green I Master kit and a LightCycler480
instrument (Roche) according to the manufacturer’s instructions. The
DDCTmethod was used to calculate the fold change in expression level
of APOBEC3 relative to GAPDH and normalized to an untreated cali-
brator sample.
APOBEC Knockdown and Overexpression
Four separate mouse unique 29-mer shRNA retroviral constructs and
a single scrambled shRNA-encoding retroviral construct (OriGene,
Rockville, Maryland) were transfected into the GP+E86 ecotropic
packaging cell line, and supernatant was used to infect B16TK cells
to generate the B16TK (shRNA APOBEC3) and B16TK (scrambled
shRNA) populations, respectively. In addition, a single scrambled
negative control non-effective shRNA cassette was similarly packaged
and used to infect B16TK cells to generate B16TK (scrambled
shRNA) cells.
B16TK tumor cell lines were engineered to overexpress hAPOBEC3B
or a catalytically inactive form of the protein APOBEC3B MUT,
following infection with either pBABE-Hygro APOBEC3B or
pBABE-Hygro APOBEC3B MUT, provided by Dr. Reuben Harris43
(Figure 6A). Forty-eight hours after infection, bulk populationsof cells were selected in hygromycin for 2 weeks and used for
experiments.
DIP Assay
B16-APOBEC3B MUT-overexpressing or B16-APOBEC3B-overex-
pressing cells were infected with VSV-GFP at an MOI of 0.01 and
incubated for 24 hr. Supernatant was collected, and 1 mL of superna-
tant was used to infect a fresh monolayer of cells. This was repeated
out to ﬁve passages. The DIP assay was done by serially diluting pas-
sage 1 and passage 5 of VSV-GFP from B16-APOBEC3B MUT or
B16-APOBEC3B cells (1:10 to 1:100,000). Fresh BHK cells were
seeded the day before in triplicate wells, and diluted viral supernatants
were allowed to adsorb for 1 hr. Stock VSV-GFP virus was then added
at anMOI of 20 (8 105 PFU/well) and incubated for 1 hr. Cells were
then washed 3 in PBS, and fresh supernatant was added. Superna-
tant was collected 24 hr after infection and titered by plaque assay by
limiting dilution on BHK cells.
In Vivo Experiments
All in vivo studies were approved by the Institutional Animal Care
and Use Committee at Mayo Clinic. Mice were challenged subcutane-
ously with 2  105 B16TK melanoma cells in 100 mL PBS (HyClone,
Logan, Utah). All virus injections were delivered intratumorally in a
50 mL volume. Tumors were measured 3 per week, and mice were
euthanized when tumors reached 1.0 cm in diameter. Mice were sacri-
ﬁced upon emergence of neurological symptoms or weight loss.
Statistics
Survival curves were analyzed by the log-rank test. Student’s t tests,
one-way ANOVA, and two-way ANOVAwere applied for in vitro as-
says as appropriate. Statistical signiﬁcance was set at p < 0.05 for all
experiments.
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